ArticleTrials2007

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.

Vera Hirsh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.